VACCELERATE Clinical Studies

Clinical trials serve the purpose of clarifying open questions regarding new vaccines, therapies or medicines. By participating in clinical trials, you can make a major contribution to scientific progress. As a study participant you support the research of diseases and the development of new treatment options and at the same time receive comprehensive medical care.

VACCELERATE is carrying out three COVID-19 vaccine trials. The results will be linked here as soon as they are published. 

STUDY 1: EU-COVAT-1 AGED

A Multinational, Phase 2, Randomised, Adaptive Protocol to Evaluate Immunogenicity and Reactogenicity of Different COVID-19 Vaccines Administration in Older Adults (≥75) Already Vaccinated Against SARS-CoV-2

Lead: Oliver Cornely, Institution/Sponsor: UHC, Germany

Details: 

A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE network – PubMed (nih.gov)

https://portal.uni-koeln.de/en/universitaet/aktuell/press-releases/single-news/studie-zur-wirksamkeit-der-boosterimpfung-gegen-corona-startet

https://clinicaltrials.gov/ct2/show/NCT05160766?cond=Covat+aged&draw=2&rank=1

Publications: 

STUDY 2: EU-COVAT-2 BOOSTAVAC

An International Multicentre, Phase 2, Randomised, Adaptive Protocol to determine the need for, optimal timing of and immunogenicity of administering a booster mRNA vaccination dose against SARS-CoV-2 in the general population (18+ years) already vaccinated against SARS-CoV-2

Lead: Patrick Mallon, Institution/Sponsor: NUID UCD, Ireland

EudraCT-number: 2021-004889-35

Details:

https://twitter.com/vaccelerate_eu/status/1503688207506063360

https://www.ucd.ie/research/news/2022/vacceleratesecondphaseiitrialboostavacstartsinireland/body,615411,en.html

https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-004889-35/IE

STUDY 3: EU-COVPT-1 COVACC

A Phase 2, Comparative Randomised Trial to Evaluate the Impact of Reduced COVID‐19 mRNA Vaccination Regimen on Immunological Responses and Reactogenicity in Paediatric Subjects with Prior SARS‐CoV‐2 Immunity

Lead: Patricia Bruijning-Verhagen, Institution/Sponsor: UMCU, Netherlands

EudraCT number: 2021-005043-71

COVID-19 Point Prevalence Germany

https://link.springer.com/article/10.1007/s15010-022-01931-7

VACCELERATE Mpox Initiatives

All information on the VACCELERATE mpox initiatives including the mpox standard, ooperations and publications can be found here: https://vaccelerate.eu/mpox/

Press Releases and Articles on the VACCELERATE Clinical Studies

Publication Video: https://www.youtube.com/watch?v=xTTTNcENoSc